Home Cart Sign in  
Chemical Structure| 2216712-66-0 Chemical Structure| 2216712-66-0

Structure of Elexacaftor
CAS No.: 2216712-66-0

Chemical Structure| 2216712-66-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Elexacaftor (VX-445) is a modulator of the cystic fibrosis transmembrane conductance regulator (CFTR). It facilitates the processing and trafficking of CFTR, increasing its presence at the cell surface.

Synonyms: VX-445

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Elexacaftor

CAS No. :2216712-66-0
Formula : C26H34F3N7O4S
M.W : 597.65
SMILES Code : CC(C)(C(F)(F)F)COC1=NN(C=C1)C2=NC(N3C(C)(C)C[C@H](C)C3)=C(C=C2)C(NS(C4=CN(C)N=C4C)(=O)=O)=O
Synonyms :
VX-445
MDL No. :MFCD32067875
InChI Key :MVRHVFSOIWFBTE-INIZCTEOSA-N
Pubchem ID :134587348

Safety of Elexacaftor

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Mouse embryonic lung explants 10 μM 72 h To investigate the effect of ETI on lung branching and terminal bud dilation in mouse embryonic lung explants, results showed that ETI significantly decreased lung branching and increased terminal bud dilation. PMC9743190
F508del HBE cells 2μM 3 days ETI treatment significantly reduced the mucin concentration in F508del HBE cells, but ASL pH did not change significantly. PMC8859811
HEK-BK cells 5 μM VX-445 significantly increased BKCa currents in HEK-BK cells, which were completely inhibited by paxilline, indicating that VX-445 directly enhances BKCa channel activity. PMC11324306
F508del CFTR HBEs 10 μM VX-445 induced K+ secretion in F508del CFTR HBEs, which was inhibited by paxilline, indicating that VX-445 promotes K+ secretion by activating BKCa channels. PMC11324306
WT CFTR HBEs 10 μM VX-445 stimulated K+ secretion, which was completely inhibited by paxilline, indicating that VX-445 promotes K+ secretion by activating BKCa channels. PMC11324306
Primary CF human bronchial epithelial (HBE) cells 3 µM 24 h To assess the restoration of CFTR activity and chloride secretion by ETI, results showed that ETI significantly increased forskolin-induced CFTR currents. PMC11647873
T465N/Q39X rectal organoid-derived monolayers 3 μM 20-24 h To evaluate the response of the T465N/Q39X genotype to Elexacaftor/Tezacaftor/Ivacaftor (ETI) treatment, results showed that ETI treatment substantially improved CFTR-mediated anion secretion and increased the rescue of mature CFTR expression. PMC11401437
S737F/Dele22-24 rectal organoid-derived monolayers 3 μM 20-24 h To evaluate the response of the S737F/Dele22-24 genotype to Elexacaftor/Tezacaftor/Ivacaftor (ETI) treatment, results showed that ETI treatment significantly increased CFTR-mediated anion secretion, with Isc values approaching non-CF samples. PMC11401437
S737F/W1282X rectal organoid-derived monolayers 3 μM 20-24 h To evaluate the response of the S737F/W1282X genotype to Elexacaftor/Tezacaftor/Ivacaftor (ETI) treatment, results showed that ETI treatment significantly increased CFTR-mediated anion secretion, with Isc values approaching non-CF samples. PMC11401437
Human CF airway epithelia 3 μM 48 h To assess the effect of TNF-α and IL-17 on CFTR modulators, the results showed that the triple combination further increased pHASL PMC8363270

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.67mL

0.33mL

0.17mL

8.37mL

1.67mL

0.84mL

16.73mL

3.35mL

1.67mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories